Published Erratum
doi: 10.1186/s13046-025-03469-6.
Correction: Intravesical instillation-based mTOR-STAT3 dual targeting for bladder cancer treatment
Affiliations
- PMID: 40676701
- PMCID: PMC12269282
- DOI: 10.1186/s13046-025-03469-6
Item in Clipboard
Published Erratum
Correction: Intravesical instillation-based mTOR-STAT3 dual targeting for bladder cancer treatment
J Exp Clin Cancer Res.
.
No abstract available
Figures
Incorporation of bispecific shRNA into replication-competent adenovirus A Genetic construction of bispecific shRNA (bs_shRNA)-expressing adenovirus (BSV). The human telomerase promoter was encoded in the front of E1A-IRES-E1B, and the U6 promoter was used for the shRNA expression in E3. In CV, the shRNA coding region was replaced by a GFP-coding sequence. Refer to preparation of replication-competent adenovirus in methods for detail method. B Normal cells (PrEC and HUEpC) and cancer cells (C4-2B and 253 J-BV) were infected by 20 MOI of CV for 72 h. C Viral vector concentration (MOI)-based cell viability test: HUEpC and 253 J-BV cells were treated with 5 MOI of CV and BSV for 72 h. D Suppression of the expression of mTOR and STAT3 as indicated by real-time PCR. For this analysis, 253 J-BV cells were treated with 5 MOI CV and BSV for 72 h. E Western blotting revealing the changes between BSV- and CV-induced mTOR and STAT3 downregulation following the treatment of 253 J-BV cells with 5 MOI CV and BSV for 72 h. F, G Viral vector concentration (MOI)-based cell viability test using crystal violet staining (F) and cell viability assay (G). The 253 J-BV cells were treated with viruses for 72 h in a concentration-dependent manner (for statistics, two-tailed t-test for C, D)
Incorporation of bispecific shRNA into replication-competent adenovirus A Genetic construction of bispecific shRNA (bs_shRNA)-expressing adenovirus (BSV). The human telomerase promoter was encoded in the front of E1A-IRES-E1B, and the U6 promoter was used for the shRNA expression in E3. In the CV construct, the shRNA cassette under the U6 promoter was replaced with a GFP cassette driven by the CMV promoter. Refer to preparation of replication-competent adenovirus in methods for detail method. B Normal cells (PrEC and HUEpC) and cancer cells (C4-2B and 253 J-BV) were infected by 20 MOI of CV for 72 h. C Viral vector concentration (MOI)-based cell viability test: HUEpC and 253 J-BV cells were treated with 5 MOI of CV and BSV for 72 h. D Suppression of the expression of mTOR and STAT3 as indicated by real-time PCR. For this analysis, 253 J-BV cells were treated with 5 MOI CV and BSV for 72 h. E Western blotting revealing the changes between BSV- and CV-induced mTOR and STAT3 downregulation following the treatment of 253 J-BV cells with 5 MOI CV and BSV for 72 h. F, G Viral vector concentration (MOI)-based cell viability test using crystal violet staining (F) and cell viability assay (G). The 253 J-BV cells were treated with viruses for 72 h in a concentration-dependent manner (for statistics, two-tailed t-test for C, D)
Erratum for
-
Intravesical instillation-based mTOR-STAT3 dual targeting for bladder cancer treatment.J Exp Clin Cancer Res. 2024 Jun 18;43(1):170. doi: 10.1186/s13046-024-03088-7. J Exp Clin Cancer Res. 2024. PMID: 38886756 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous
